A Randomized, Single-Blind Study to Evaluate the Pharmacokinetics (PK), and Pharmacodynamics (PD) of INS1007 Administered for 12 Weeks in Subjects with Granulomatosis with Polyangiitis (GPA)
Latest Information Update: 09 Oct 2019
At a glance
- Drugs Brensocatib (Primary)
- Indications Granulomatosis with polyangiitis
- Focus Biomarker; Pharmacodynamics
- Sponsors Insmed
Most Recent Events
- 06 Oct 2019 Status changed from recruiting to discontinued.
- 17 Jun 2019 Status changed from planning to recruiting.
- 30 May 2019 New trial record